Study guide
2.2 Informed Consent Process and Documentation
Certified Clinical Research Coordinator CCRC
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Scientific Concepts and Research Design
1.1 Protocol Elements 1.2 Study Design and Objectives 1.3 Study Endpoints and Biostatistics
2 Chapter 2: Ethical Principles and Guidelines
2.1 Ethical Principles (Declaration of Helsinki, Belmont Report) 2.2 Informed Consent Process and Documentation 2.3 Vulnerable Populations and Assent
3 Chapter 3: IRB/IEC Oversight and Participant Safety
3.1 IRB/IEC Functions and Oversight 3.2 Adverse Event Classification and Reporting 3.3 Safety Monitoring and Safety Reporting
4 Chapter 4: Participant Rights and Ethics
4.1 Participant Rights and Confidentiality (HIPAA/GDPR) 4.2 Conflicts of Interest 4.3 Ethical Scenarios in Clinical Trials
5 Chapter 5: Product Development and Regulatory Framework
5.1 Drug and Device Development Phases 5.2 U.S. and International Regulatory Frameworks 5.3 Investigational Product Investigator's Brochure (IB)
6 Chapter 6: Investigational Product Accountability
6.1 Investigational Product Labeling and Storage 6.2 Investigational Product Receipt, Dispensing, and Accountability 6.3 Investigational Product Return and Destruction
7 Chapter 7: Regulatory Submissions and Actions
7.1 Regulatory Submissions (IND, NDA, IDE, PMA) 7.2 Regulatory Actions and Compliance 7.3 Pharmacokinetics and Pharmacodynamics in Product Development
8 Chapter 8: Clinical Trial Operations and GCP Principles
8.1 Introduction to ICH E6 GCP Principles (including R3 updates) 8.2 Investigator Responsibilities under GCP 8.3 Sponsor Responsibilities and Oversight
9 Chapter 9: Essential Documents and Site Qualification
9.1 Essential Documents (Pre-study, During, Post-study) 9.2 Site Selection and Qualification 9.3 Quality Management and Standard Operating Procedures (SOPs)
10 Chapter 10: Protocol Deviations and Amendments
10.1 Protocol Adherence and Compliance 10.2 Protocol Deviations and Violations 10.3 Protocol Amendments and Version Control
11 Chapter 11: Monitoring Visits and Audits
11.1 Monitoring Preparation and Visit Types 11.2 Monitoring Visits (SIV, IMV, COV) 11.3 Regulatory Inspections and Site Audits
12 Chapter 12: Study and Site Management - Startup
12.1 Site Startup Operations 12.2 Site Budget and Contract Management 12.3 Site Staffing, Training, and Documentation
13 Chapter 13: Enrollment and Recruitment
13.1 Enrollment Management and Strategies 13.2 Participant Recruitment and Retention 13.3 Participant Compensation and Ethics
14 Chapter 14: Daily Trial Coordination
14.1 Visit Scheduling and Logistics 14.2 Equipment Maintenance and Calibration 14.3 Specimen Handling and Shipping (IATA/dangerous goods)
15 Chapter 15: Quality Improvement and Site Closeout
15.1 Participant Safety Management 15.2 Quality Improvement and Site Audits Preparation 15.3 Study and Site Closeout Procedures
16 Chapter 16: Source Documentation and Case Report Forms
16.1 Source Documentation Standards (ALCOA-C) 16.2 Case Report Forms and eCRF Completion 16.3 Electronic Data Capture (EDC) Systems
17 Chapter 17: Data Management and Queries
17.1 Data Management Processes 17.2 Data Queries and Discrepancy Resolution 17.3 Data Correction and Audit Trails
18 Chapter 18: Data Privacy and Records Retention
18.1 Data Privacy and Confidentiality 18.2 Records Retention and Archiving 18.3 Compliance in Clinical Trial Informatics
2.2 Informed Consent Process and Documentation
Key Takeaways Explain This Topic AI
Informed consent is an ongoing process of communication, not merely the signing of a document.
ICH E6(R3) section 2.8.10 lists the elements the informed consent discussion and written materials should explain, as applicable.
Before participation, the participant (or legally acceptable representative) and the person who conducted the consent discussion each sign and date the current, IRB-approved form, physically or electronically.
Last updated: October 2026
The Informed Consent Process
Informed consent is frequently misunderstood as a simple legal hurdle—a form to be signed before a procedure can commence. In the realm of clinical research, informed consent is an ongoing process of robust communication between the investigator (or their delegated staff, such as the CRC) and the subject. This process begins at the very first point of contact, continues throughout the trial, and only concludes when the subject's participation ends.
The Core Philosophy
The fundamental goal of the informed consent process is to empower individuals to make an educated, voluntary, and autonomous decision regarding their participation in research. This philosophy aligns directly with the Belmont Report's ethical principle of Respect for Persons. The process must be conducted under circumstances that provide the subject with sufficient time and opportunity to consider whether or not to participate, effectively minimizing any possibility of coercion or undue influence.
Essential Elements of Informed Consent
Under both United States FDA regulations (21 CFR 50.25) and ICH E6(R3) (section 2.8.10), an informed consent form (ICF) and the corresponding verbal discussion must include several essential elements to be considered valid:
Research Statement: A clear, unambiguous statement that the study involves research. This includes an explanation of the purposes of the research, the expected duration of the subject's participation, a step-by-step description of the procedures to be followed, and clear identification of any procedures which are experimental rather than standard of care.
Reasonably Foreseeable Risks: A thorough description of any reasonably foreseeable risks or discomforts to the subject. This includes physical risks (e.g., side effects of an investigational drug), psychological risks, or social risks (e.g., breach of confidentiality).
Anticipated Benefits: A realistic description of any benefits to the subject or to others which may reasonably be expected from the research. It must be explicitly clear if there is no direct clinical benefit expected for the participating subject.
Alternative Procedures/Treatments: A full disclosure of appropriate alternative procedures or courses of treatment, if any, that might be advantageous to the subject. Subjects must know what their options are outside of the clinical trial.
Confidentiality: A statement describing the extent, if any, to which confidentiality of records identifying the subject will be maintained. It must also note the specific possibility that regulatory bodies like the FDA, the study sponsor, and the IRB may inspect the medical records.
Compensation and Medical Treatment: An explanation of whether any compensation and any medical treatment are available if a research-related injury occurs and, if so, what they consist of, or where further information may be obtained. (US FDA rules require this element for research involving more than minimal risk; ICH E6(R3) lists it without that limit.)
Contacts: A clear explanation of whom to contact for answers to pertinent questions about the research and research subjects' rights, and precisely whom to contact in the event of a research-related injury to the subject (typically the Principal Investigator or a 24-hour study hotline).
Voluntary Participation: A forceful statement that participation is entirely voluntary, that refusal to participate will involve no penalty or loss of benefits to which the subject is otherwise entitled, and that the subject may discontinue participation at any time without penalty or loss of benefits.
ICH E6(R3) 2.8.10 also asks, as applicable, for: what is expected of participants; any anticipated expenses and prorated payments; how the participant's data will be handled, including if they withdraw; that monitors, auditors, regulators and (where applicable) the IRB/IEC will have direct access to their source records, with confidentiality safeguarded; and that trial results and information on their actual treatment will be made available if they want them.
Additional Elements (When Appropriate)
Depending on the nature of the trial, additional elements may be required:
A statement that the particular treatment or procedure may involve risks to the subject (or embryo/fetus) which are currently unforeseeable.
Anticipated circumstances under which the subject's participation may be terminated by the investigator without regard to the subject's consent (e.g., if the subject's health deteriorates).
Any additional financial costs to the subject that may result from participation in the research.
The consequences of a subject's decision to withdraw early from the research and procedures for orderly termination of participation.
A statement that significant new findings developed during the course of the research which may relate to the subject's willingness to continue participation will be provided to the subject.
The approximate number of participants involved in the trial.
Conducting the Consent Discussion
As a CRC often tasked with facilitating the consent process, adhering to best practices is vital for compliance and ethical conduct:
Environment: Ensure a quiet, private setting for the discussion, free from clinical interruptions.
Language: The written and verbal information must be in language understandable to the subject. Avoid medical jargon (e.g., use 'bruise' instead of 'contusion'). If the subject is non-English speaking, an IRB-approved translated ICF and a qualified interpreter must be used.
Pacing: Allow ample time for the subject to read the form, ask questions, and consult with family members or their primary care physician before making a decision. Never rush a subject.
Assessment of Comprehension: Do not simply ask, 'Do you understand?' which usually elicits a passive 'yes.' Instead, use the 'teach-back' method. Ask the subject to explain in their own words what the study is about, the major risks, and what their obligations will be.
Documentation of Informed Consent
The documentation process is heavily scrutinized during sponsor monitoring visits and regulatory inspections. It must be executed flawlessly:
Use the Current Version: Ensure the subject is reading and signing the most recently IRB-approved version of the ICF.
Signatures and Dates: Before participation, the participant (or legally acceptable representative) signs and dates the ICF, and so does the investigator or delegated staff member who conducted the consent discussion; an impartial witness also signs and dates where one is needed (ICH E6(R3) 2.8.7). Signatures and dates may be physical or electronic. Each person signs and dates for themselves: a CRC never signs or dates for the participant.
Providing a Copy: The subject must be given a copy of the signed and dated ICF for their records. The original is securely kept in the investigator's site file or the subject's medical record, depending on institutional policy.
Process Note: It is considered an essential best practice to write a detailed 'consent process note' in the subject's source documentation. This note should state who was present, that all questions were answered adequately, that no study-specific procedures were performed prior to consent being obtained, and that a copy of the signed form was provided.
Re-Consent
Because informed consent is an ongoing process, if new information becomes available that may affect a participant's willingness to continue (e.g., a newly discovered serious side effect, or a major change in study procedures), the participant must be informed in a timely manner, and that communication and their decision to continue are documented (ICH E6(R3) 2.8.2). The new information is then assessed to decide whether re-consent is needed; depending on the stage of the trial, it may matter only to new participants. If re-consent is needed, the revised consent materials clearly identify the new information, and the IRB/IEC must approve them before they are used.